Tacrolimus and Methotrexate for the Prophylaxis of Graft-Versus-Host Disease After Unrelated Donor Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Takehiko Mori, Y. Aisa, T. Nakazato, Rie Yamazaki, Takayuki Shimizu, A. Mihara, A. Yamane, Y. Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m2 on day 1, 10 mg/m2 on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis. The median number of nucleated cells in infused cord blood was 2.66 × 107/kg (range 1.90 to 4.15 × 107/kg). Engraftment was achieved in 16 of 18 patients. The median time to absolute neutrophil count >0.5 × 109/L was 21.5 days (range 17 to 32), and the median time to platelet count >2.0 × 109/L was 36 days (range 26 to 57). Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD. The cumulative incidence of grade II acute GVHD was 44.4%. Chronic GVHD occurred in 7 of 15 evaluable patients: limited type in three patients, extensive type in four patients. Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days). The probability of disease-free survival at 2 years was 79.1%. These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.

Original languageEnglish
Pages (from-to)1615-1619
Number of pages5
JournalTransplantation Proceedings
Volume39
Issue number5
DOIs
Publication statusPublished - 2007 Jun

Fingerprint

Unrelated Donors
Tacrolimus
Graft vs Host Disease
Hematologic Neoplasms
Fetal Blood
Methotrexate
Transplantation
Platelet Count
Disease-Free Survival
Neutrophils
Survival Rate
Retrospective Studies
Cell Count
Incidence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

@article{1d127354c6064eafb88b4af773b02694,
title = "Tacrolimus and Methotrexate for the Prophylaxis of Graft-Versus-Host Disease After Unrelated Donor Cord Blood Transplantation for Adult Patients With Hematologic Malignancies",
abstract = "Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m2 on day 1, 10 mg/m2 on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis. The median number of nucleated cells in infused cord blood was 2.66 × 107/kg (range 1.90 to 4.15 × 107/kg). Engraftment was achieved in 16 of 18 patients. The median time to absolute neutrophil count >0.5 × 109/L was 21.5 days (range 17 to 32), and the median time to platelet count >2.0 × 109/L was 36 days (range 26 to 57). Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD. The cumulative incidence of grade II acute GVHD was 44.4{\%}. Chronic GVHD occurred in 7 of 15 evaluable patients: limited type in three patients, extensive type in four patients. Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days). The probability of disease-free survival at 2 years was 79.1{\%}. These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.",
author = "Takehiko Mori and Y. Aisa and T. Nakazato and Rie Yamazaki and Takayuki Shimizu and A. Mihara and A. Yamane and Y. Ikeda and Shinichiro Okamoto",
year = "2007",
month = "6",
doi = "10.1016/j.transproceed.2006.12.042",
language = "English",
volume = "39",
pages = "1615--1619",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Tacrolimus and Methotrexate for the Prophylaxis of Graft-Versus-Host Disease After Unrelated Donor Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

AU - Mori, Takehiko

AU - Aisa, Y.

AU - Nakazato, T.

AU - Yamazaki, Rie

AU - Shimizu, Takayuki

AU - Mihara, A.

AU - Yamane, A.

AU - Ikeda, Y.

AU - Okamoto, Shinichiro

PY - 2007/6

Y1 - 2007/6

N2 - Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m2 on day 1, 10 mg/m2 on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis. The median number of nucleated cells in infused cord blood was 2.66 × 107/kg (range 1.90 to 4.15 × 107/kg). Engraftment was achieved in 16 of 18 patients. The median time to absolute neutrophil count >0.5 × 109/L was 21.5 days (range 17 to 32), and the median time to platelet count >2.0 × 109/L was 36 days (range 26 to 57). Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD. The cumulative incidence of grade II acute GVHD was 44.4%. Chronic GVHD occurred in 7 of 15 evaluable patients: limited type in three patients, extensive type in four patients. Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days). The probability of disease-free survival at 2 years was 79.1%. These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.

AB - Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m2 on day 1, 10 mg/m2 on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis. The median number of nucleated cells in infused cord blood was 2.66 × 107/kg (range 1.90 to 4.15 × 107/kg). Engraftment was achieved in 16 of 18 patients. The median time to absolute neutrophil count >0.5 × 109/L was 21.5 days (range 17 to 32), and the median time to platelet count >2.0 × 109/L was 36 days (range 26 to 57). Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD. The cumulative incidence of grade II acute GVHD was 44.4%. Chronic GVHD occurred in 7 of 15 evaluable patients: limited type in three patients, extensive type in four patients. Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days). The probability of disease-free survival at 2 years was 79.1%. These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.

UR - http://www.scopus.com/inward/record.url?scp=34250168952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250168952&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.12.042

DO - 10.1016/j.transproceed.2006.12.042

M3 - Article

C2 - 17580201

AN - SCOPUS:34250168952

VL - 39

SP - 1615

EP - 1619

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -